Company profile: Surface Oncology
1.1 - Company Overview
Company description
- Provider of next-generation cancer immunotherapy treatments based on proprietary insights into novel immunotherapy targets and emerging areas of cancer immuno-biology, advancing multiple preclinical programs with world-leading scientific founders.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Surface Oncology
Vitaeris
HQ: Canada
Website
- Description: Provider of clinical-stage biopharmaceutical development by a Canadian company focused on the anti-interleukin-6 monoclonal antibody Clazakizumab, with global exclusive rights licensed from Alder Biopharmaceuticals, pursuing applications in chronic inflammatory diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vitaeris company profile →
Ab Initio Biotherapeutics
HQ: United States
Website
- Description: Provider of antigen discovery and antibody generation solutions using a proprietary platform targeting multi-transmembrane proteins such as GPCRs, supporting therapeutics for neurological, cardiovascular, endocrine and gastrointestinal disorders; offerings include antibody optimization, single B-cell screening of immune repertoires, the OmniAb Discovery Platform, OmniRat and OmniMouse with high-throughput screening.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ab Initio Biotherapeutics company profile →
Sutro Biopharma
HQ: United States
Website
- Description: Provider of protein therapeutics leveraging OCFS and XpressCF cell-free protein synthesis, with an ADC pipeline: luveltamab tazevibulin (luvelta) targeting folate receptor alpha in clinical studies for platinum-resistant ovarian cancer; STRO-003 (ROR1-targeting) under a global licensing agreement with potential milestones and royalties; STRO-004 (tissue factor-targeting) planned for 2025 IND; plus sustainability efforts and a summer internship program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sutro Biopharma company profile →
Diamyd Medical
HQ: Sweden
Website
- Description: Provider of antigen-specific immunotherapies and regenerative therapies for Type 1 Diabetes based on the GAD molecule and GABA technology. Products include Diamyd to preserve insulin production and Remygen for regeneration/immunomodulation. Offers GMP-manufactured GAD65 protein for preclinical research and conducts DIAGNODE-3 (Phase III intralymphatic Diamyd) and DiaPrecise (Phase II prevention) trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diamyd Medical company profile →
Trillium Therapeutics
HQ: Canada
Website
- Description: Provider of biopharmaceutical research and development focused on immune system regulation and the discovery and development of protein therapeutics—including monoclonal antibodies, secreted proteins, and peptides—for cancer and autoimmune indications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trillium Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Surface Oncology
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Surface Oncology
2.2 - Growth funds investing in similar companies to Surface Oncology
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Surface Oncology
4.2 - Public trading comparable groups for Surface Oncology
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →